Form S-8 Trevi Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Raymond James Reiterates Strong Buy Rating on Trevi Therapeutics (TRVI)
March 19, 2025 7:22 AM EDTRaymond James analyst Ryan Deschner reiterated a Strong Buy rating and $29.00 price target on Trevi Therapeutics (NASDAQ: TRVI).
The analyst comments "We remain Strong Buy rated on TRVI following 4Q24 earnings. Our bullish thesis that Haduvio could potentially become the go-to... More
